Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 297, Issue 1-2, Pages 137-140Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2008.11.018
Keywords
GLP-1 analogue; Hypoglycaemia; Body weight; Systolic blood pressure
Categories
Funding
- Novo Nordisk A/S, Bagsvaerd, Denmark
Ask authors/readers for more resources
Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue with high homology to native GLP-1, has structural modifications sufficient to amend pharmacokinetics for once-daily administration without compromising biological activity. Data from large, controlled, clinical Studies have confirmed the therapeutic profile of liraglutide, with robust reductions in HbA(1c), low risk of hypoglycaemia and clinically relevant reductions in body weight and systolic blood pressure. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available